Landis John B.'s most recent trade in EyePoint Pharmaceuticals Inc was a trade of 40,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 21,400 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,000 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Landis B. John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 25,014 | 25,014 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Landis John B. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 26,100 | 26,100 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 11,400 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 3,000 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 8,400 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 2,500 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 2,500 | 2,500 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 5,900 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | John B. Landis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,900 | 0 | - | - | Restricted Stock Units |